Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial

By Adria Calatayud

Sanofi said its rilzabrutinib drug candidate met a primary goal of a late-stage clinical trial in immune thrombocytopenia, a blood disorder, paving the way for regulatory submissions later this year.

The French pharmaceutical giant said Tuesday that a phase 3 trial showed a significantly higher proportion of patients that received rilzabrutinib achieved the primary goal of durable platelet response compared to those that received placebo.

The safety profile of the drug was consistent with previous studies, the company said.

The company said this highlights the potential of the drug to provide a clinically meaningful benefit to patients with persistent or chronic immune thrombocytopenia.

Sanofi plans regulatory submissions in the U.S. and the European Union by the end of the year.

Write to Adria Calatayud at adria.calatayud@wsj.com

(END) Dow Jones Newswires

April 23, 2024 01:38 ET (05:38 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.